The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Journal: Evidence-based Cardiology. 2018;11(4): 4‑9

Read: 4339 times

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

. Evidence-based Cardiology. 2018;11(4):4‑9. (In Russ.)

МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Close metadata

References:

  1. Han S., Hagan D.L., Taylor J.R., et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008;57:1723—1729.
  2. Komoroski B., Vachharajani N., Feng Y., et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2009;85:513—519.
  3. Plosker G.L. Dapagliflozin: a review of its use in patients with type 2 diabetes. Drugs 2014;74:2191—209.
  4. Zinman B., Wanner C., Lachin J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117—2128.
  5. Neal B., Perkovic V., Mahaffey K.W., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644—657.
  6. Mahaffey K.W., Neal B., Perkovic V., et al. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin Cardiovascular Assessment Study). Circulation 2018;137:323—334.
  7. Perkovic V., de Zeeuw D., Mahaffey K.W., et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS program randomised clinical trials. Lancet Diabetes Endocrinol 2018; 6:691—704.
  8. Cherney D.Z.I., Zinman B., Inzucchi S.E., et al. Effects of empagliflozin on the urinary albumin-to creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 2017;5:610—621.
  9. Wanner C., Inzucchi S.E., Lachin J.M., et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016;375:323—334.
  10. American Diabetes Association. 9. Cardiovascular disease and risk management: standards of medical care in diabetes — 2018. Diabetes Care 2018;41:Suppl 1:S86—S104.
  11. American Diabetes Association. 8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes — 2018. Diabetes Care 2018;41:Suppl 1:S73—S85.
  12. Ponikowski P., Voors A.A., Anker S.D., et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37: 2129—2200.
  13. Garber A.J., Abrahamson M.J., Barzilay J.I., et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm: 2018 executive summary. Endocr Pract 2018;24:91—120.
  14. Imprialos K.P., Boutari C., Stavropoulos K., et al. Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality? J Neurol Neurosurg Psychiatry 2017;88:249—253.
  15. Khouri C., Cracowski J.L., Roustit M. SGLT-2 inhibitors and the risk of lower-limb amputation: is this a class effect? Diabetes Obes Metab 2018;20:1531—1534.
  16. Garg S.K., Peters A.L., Buse J.B., Danne T. Strategy for mitigating DKA risk in patients with type 1 diabetes on adjunctive treatment with SGLT inhibitors: a STICH protocol. Diabetes Technol Ther 2018;20:571—575.
  17. Fitchett D., Zinman B., Wanner C., et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J 2016;37:1526—1534.
  18. Fitchett D.H., Udell J.A., Inzucchi S.E. Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes. Eur J Heart Fail 2017;19:43—53.
  19. Heerspink H.J.L., Kosiborod M., Inzucchi S.E., Cherney D.Z.I. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int 2018;94:26—39.
  20. Sattar N., McGuire D.K. Pathways to cardiorenal complications in type 2 diabetes mellitus: a need to rethink. Circulation 2018;138:7—9.
  21. Bloomgarden Z. The kidney and cardiovascular outcome trials. J Diabetes 2018;10:88—89.
  22. MacIsaac R.J., Jerums G. Ekinci E.I. Cardio-renal protection with empagliflozin. Ann Transl Med 2016;4:409.
  23. Bhatt D.L., Mehta C. Adaptive designs for clinical trials. N Engl J Med 2016;375:65—74.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.